|

Fontan-Sprechstunde

RECRUITINGN/ASponsored by University of Erlangen-Nürnberg Medical School
Actively Recruiting
PhaseN/A
SponsorUniversity of Erlangen-Nürnberg Medical School
Started2020-09-01
Est. completion2031-09-01
Eligibility
Age6 Years – 60 Years
Healthy vol.Accepted

Summary

After successful Fontan surgery, the risk of mortality in childhood is only low. Unfortunately, some of the patients suffer from Fontan-typical long-term complications in the long-term course, whereby protein loss neuropathy must be mentioned in particular, which is described in the literature with an incidence of 3-14% (1, 2) and still has a 5-year risk of death of 6-12% today (2, 3). Protein loss tereopathy leads to loss of protein in the intestine and subsequently to diarrhea and edema. Other problems concern the liver, which can develop cirrhosis due to chronic congestion (4-6). Cardiac can lead to heart failure and arrhythmias. The registry study described in this protocol is intended to identify factors that influence the treatment outcome of patients in the Fontan circulation in the long term through systematic prospective documentation of the data from our standardized and guideline-oriented treatment.

Eligibility

Age: 6 Years – 60 YearsHealthy volunteers accepted
Inclusion Criteria:

* congenital heart defect of the univentricular type that has led to Fontan circulation

Exclusion Criteria:

* no exclusion criteria

Conditions2

Heart DiseaseUniventricular Heart

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.